Forge Bi­o­log­ics con­tin­ues its hot streak with $90M round to boost gene ther­a­py man­u­fac­tur­ing ser­vices

Over the past two years, the Ohio-based gene ther­a­py man­u­fac­tur­er Forge Bi­o­log­ics has man­aged to get a large amount of cap­i­tal to scale up its AAV pro­duc­tion ca­pa­bil­i­ties. And as the field con­tin­ues to grow, the com­pa­ny looks to grow along with it.

The com­pa­ny an­nounced Mon­day that it has raised $90 mil­lion in a Se­ries C fund­ing round, bring­ing the to­tal amount raised so far to $330 mil­lion. In an in­ter­view with End­points News, Forge Bi­o­log­ics CEO Tim Miller said that the round it­self took on­ly a few months to put to­geth­er as firms had ap­proached Forge to par­tic­i­pate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER